Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-κB and -MAPK signaling pathways

Liver International

Volumn 26, Issue 4, 2006, Pages 467-476

  Yokoyama, Terufumi ^a   Komori, Atsumasa ^a,b   Nakamura, Minoru ^a,b   Takii, Yasushi ^a   Kamihira, Takashi ^a   Shimoda, Shinji ^c   Mori, Tsuyoshi ^a   Fujiwara, Shinsuke ^a,b   Koyabu, Makiko ^a   Taniguchi, Ken ^a   Fujioka, Hikaru ^a,b   Migita, Kiyoshi ^a,b   Yatsuhashi, Hiroshi ^a,b   Ishibashi, Hiromi ^a,b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Cytokine chemokine; Human intrahepatic biliary epithelial cell; Innate immunity; Primary biliary cirrhosis; Toll like receptor

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CD14 ANTIGEN; CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN MD 2; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ARTICLE; BILE DUCT DISEASE; BILIARY CIRRHOSIS; CELL STIMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INNATE IMMUNITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BILE DUCT DISEASES; BILE DUCTS, INTRAHEPATIC; CELLS, CULTURED; CHEMOKINE CCL2; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; NITRILES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONES; TEICHOIC ACIDS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 33645741989     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01254.x     Document Type: Article

References (33)

1. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002; 1589: 1-13.
2. Anderson K V. Toll signaling pathways in the innate immune response. Curr Opin Immunol 2000; 12: 13-9.
3. Zhang D, Zhang G, Hayden M S, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303: 1522-6.
4. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004; 4: 499-511.
5. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 2004; 430: 257-63.
6. Tabeta K, Georgel P, Janssen E, et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004; 101: 3516-21.
7. Chow J C, Young D W, Golenbock D T, Christ W J, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274: 10689-92.
8. Jiang Q, Akashi S, Miyake K, Petty H R. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 2000; 165: 3541-4.
9. Cario E, Podolsky D K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-7.
10. Hausmann M, Kiessling S, Mestermann S, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002; 122: 1987-2000.
11. Podolsky D K. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29
12. Schilling J D, Mulvey M A, Vincent C D, Lorenz R G, Hultgren S J. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J Immunol 2001; 166: 1148-55.
13. Otte J M, Cario E, Podolsky D K. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 2004; 126: 1054-70.
14. Kumar M V, Nagineni C N, Chin M S, Hooks J J, Detrick B. Innate immunity in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol 2004; 153: 7-15.
15. Kusumoto Y, Hirano H, Saitoh K, et al. Human gingival epithelial cells produce chemotactic factors interleukin-8 and monocyte chemoattractant protein-1 after stimulation with Porphyromonas gingivalis via toll-like receptor 2. J Periodontol 2004; 75: 370-9.
16. Sha Q, Truong-Tran A Q, Plitt J R, Beck L A, Schleimer R P. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004; 31: 358-64.
17. Young S L, Lyddon T D, Jorgenson R L, Misfeldt M L. Expression of toll-like receptors in human endometrial epithelial cells and cell lines. Am J Reprod Immunol 2004; 52: 67-73.
18. Schaefer T M, Desouza K, Fahey J V, Beagley K W, Wira C R. Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 2004; 112: 428-36.
19. Harada K, Ohira S, Isse K, et al. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Invest 2003; 83: 1657-67.
20. Yasoshima M, Kono N, Sugawara H, Katayanagi K, Harada K, Nakanuma Y. Increased expression of interleukin-6 and tumor necrosis factor-alpha in pathologic biliary epithelial cells: In situ and culture study. Lab Invest 1998; 78: 89-100.
21. Kamihira T, Shimoda S, Nakamura M, et al. Primary biliary cirrhosis: T cells are regulated via PG-E2 and programmed death 1 ligands from biliary epithelium. Hepatology 2005; 41: 151-9.
22. Schreiber E, Matthias P, Muller M M, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989; 17: 6419.
23. Izban K F, Ergin M, Qin J Z, et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: Implications for apoptosis resistance and pathogenesis. Hum Pathol 2000; 31: 1482-90.
24. Davies S P, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
25. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: An update. Biochem J 2003; 371: 199-204.
26. Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1998; 29: 409-16.
27. Hiramatsu K, Harada K, Tsuneyama K, et al. Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis. J Hepatol 2000; 33: 9-18.
28. Phillips K, Kedersha N, Shen L, Blackshear P J, Anderson P. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor α, cyclooxygenase 2, and inflammatory arthritis. Proc Natl Acad Sci USA 2004; 101: 2011-6.
29. Kawai T, Takeuchi O, Fujita T, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001; 167: 5887-94.
30. Wang A P, Migita K, Ito M, et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun 2005; 25: 85-91.
31. Takii Y, Nakamura M, Ito M, et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005; 85: 908-20.
32. Tsuneyama K, Harada K, Yasoshima M, et al. Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: Implications for pathogenesis. J Pathol 2001; 193: 102-9.
33. Terada R, Yamamoto K, Hakoda T, et al. Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases. Lab Invest 2003; 83: 665-72.